NCT05960318View on ClinicalTrials.gov

Post Market Clinical Follow-Up Study - Medical Device KalobaNaso

CompletedOBSERVATIONAL
Enrollment

131

Participants

Timeline

Start Date

May 8, 2023

Primary Completion Date

July 31, 2023

Study Completion Date

July 31, 2023

Conditions
Common ColdNasal Mucosal InflammationRhinitis
Interventions
DEVICE

KalobaNaso spray

Nasal spray, 2 puff per nostril, 3 times a day

DEVICE

KalobaNaso junior spray

Nasal spray, 1 puff per nostril, 3 times a day

Trial Locations (1)

39044

Schwabe Pharma Italia, Neumarkt

All Listed Sponsors
lead

Schwabe Pharma Italia

INDUSTRY

NCT05960318 - Post Market Clinical Follow-Up Study - Medical Device KalobaNaso | Biotech Hunter | Biotech Hunter